These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26396441)

  • 1. Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases.
    Marfatia YS; Talwar M; Agrawal M; Sharma A; Mehta K
    Indian J Sex Transm Dis AIDS; 2014; 35(2):96-9. PubMed ID: 26396441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments.
    Note R; Maisonneuve C; Lettéron P; Peytavin G; Djouadi F; Igoudjil A; Guimont MC; Biour M; Pessayre D; Fromenty B
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3384-92. PubMed ID: 14576092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line therapy and mitochondrial damage: different nucleosides, different findings.
    Blanco F; García-Benayas T; José de la Cruz J; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(1):11-9. PubMed ID: 12577192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
    Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.
    Amin J; Moore A; Carr A; French MA; Law M; Emery S; Cooper DA;
    HIV Clin Trials; 2003; 4(4):252-61. PubMed ID: 12916011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.
    Divi RL; Leonard SL; Kuo MM; Nagashima K; Thamire C; St Claire MC; Wade NA; Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):201-9. PubMed ID: 16538687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.
    Curran A; Ribera E
    Expert Opin Drug Saf; 2011 May; 10(3):389-406. PubMed ID: 21235431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
    Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
    AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The influence of long-term nucleotide reverse transcriptase inhibitors on lipids metabolism in HIV/AIDS patients].
    Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):859-62. PubMed ID: 23291022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
    Venhoff N; Setzer B; Melkaoui K; Walker UA
    Antivir Ther; 2007; 12(7):1075-85. PubMed ID: 18018766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors.
    Divi RL; Leonard SL; Kuo MM; Walker BL; Orozco CC; St Claire MC; Nagashima K; Harbaugh SW; Harbaugh JW; Thamire C; Sable CA; Poirier MC
    Cardiovasc Toxicol; 2005; 5(3):333-46. PubMed ID: 16244378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients.
    Dragovic G; Jevtovic D
    Antivir Chem Chemother; 2003 Sep; 14(5):281-4. PubMed ID: 14694991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors.
    Walker UA; Setzer B; Venhoff N
    AIDS; 2002 Nov; 16(16):2165-73. PubMed ID: 12409738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.